Evogene Slashes Annual Operating Expenses by 37% to $13.8M in FY25 Amid Strategic Pivot
Summary
Evogene reported its fourth quarter and full-year 2025 financial results, revealing a significant 37% reduction in annual operating expenses to $13.8 million, down from $22.0 million in 2024. This substantial cost cutting, which the company expects to sustain, is a direct result of a strategic shift to focus on its ChemPass AI™ platform, a pivot previously detailed in a 6-K filing on February 25, 2026. The report also confirmed the divestment of Lavie Bio and the licensing of Biomica's lead oncology candidate, further streamlining operations. For a company with a small market capitalization trading near its 52-week low, these financial improvements and strategic realignments are material, indicating a more focused and financially disciplined approach. Traders will be watching for continued execution on the ChemPass AI strategy and further progress in its pharma and agriculture collaborations.
At the time of this announcement, EVGN was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.81 to $2.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.